The effect of somatostatin analogs and acromegaly on the upper gastrointestinal system
Purpose To evaluate the effects of somatostatin analogs and disease activity status on the upper gastrointestinal system in patients with acromegaly. Methods One hundred eighty-one patients with acromegaly were retrospectively assessed. The demographic, biochemical, pathologic, and radiologic data o...
Gespeichert in:
| Veröffentlicht in: | Pituitary 2021-04, Vol.24 (2), p.184-191 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 191 |
|---|---|
| container_issue | 2 |
| container_start_page | 184 |
| container_title | Pituitary |
| container_volume | 24 |
| creator | Sahin, Serdar Icli, Tevhide Betul Durcan, Emre Sulu, Cem Ozkaya, Hande Mefkure Hatemi, Ali Ibrahim Kadioglu, Pinar |
| description | Purpose
To evaluate the effects of somatostatin analogs and disease activity status on the upper gastrointestinal system in patients with acromegaly.
Methods
One hundred eighty-one patients with acromegaly were retrospectively assessed. The demographic, biochemical, pathologic, and radiologic data of the patients were evaluated. The upper gastrointestinal endoscopies and endoscopic biopsies were investigated. We divided patients into four groups according to the use of somatostatin analogs, and into two groups according to disease activity. We compared the data of patients between groups A, B, C, and D, and controlled/uncontrolled groups separately.
Results
Before and in the peri-endoscopic period, 67 and 27 patients were being treated with octreotide long-acting release (LAR) (group A) and lanreotide autogel (group B), respectively. Twenty-one patients used somatostatin analogs, but they were stopped for various reasons before upper gastrointestinal endoscopy (group C), and 66 patients did not use a somatostatin analog (group D). In the peri-endoscopic period, 103 (60%) patients were responsive to medical and/or surgical treatment and 67 (40%) patients were non-responsive. The rate of gastritis was higher in group A than in groups B and D. The incidence of duodenitis and gastric ulcer was much higher in group D. The rate of gastritis was higher in the controlled group compared to the uncontrolled group.
Conclusion
The study showed that octreotide LAR treatment could be a risk factor in addition to known factors for the development of gastritis in patients with acromegaly. |
| doi_str_mv | 10.1007/s11102-020-01095-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2452091868</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2501660291</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-9db5e7a1ad86074b158a1f3de7d00697ffcf89e9d7c00e4768f04551ef818dd03</originalsourceid><addsrcrecordid>eNp9kM1r3DAQxUVoyObrH-ghCHrpxc2MZVnysYQ0KQR6SUJvQmuNtrvY1kaSD_vfR-nmA3roaQTze2-eHmOfEb4hgLpMiAh1BTVUgNDJShywY5RKVKoB8am8hW4r0eDvBTtJaQOFAtEcsYUQoJoG4Jg93v8hTt5Tn3nwPIXR5pCyzeuJ28kOYZXKdNz2MYy0ssOOh4nnIpq3W4p8ZVOOYT1lSkViB552KdN4xg69HRKdv85T9vDj-v7qtrr7dfPz6vtd1Qslc9W5pSRl0TrdlkRLlNqiF46UA2g75X3vdUedUz0ANarVHhopkbxG7RyIU_Z177uN4WkuGcy4Tj0Ng50ozMnUjayhQ93qgn75B92EOZbIhZKAbQt1h4Wq91T5b0qRvNnG9WjjziCYl9bNvnVTWjd_WzeiiC5ereflSO5d8lZzAcQeSGU1rSh-3P6P7TP14Y0Z</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2501660291</pqid></control><display><type>article</type><title>The effect of somatostatin analogs and acromegaly on the upper gastrointestinal system</title><source>Springer Nature - Complete Springer Journals</source><creator>Sahin, Serdar ; Icli, Tevhide Betul ; Durcan, Emre ; Sulu, Cem ; Ozkaya, Hande Mefkure ; Hatemi, Ali Ibrahim ; Kadioglu, Pinar</creator><creatorcontrib>Sahin, Serdar ; Icli, Tevhide Betul ; Durcan, Emre ; Sulu, Cem ; Ozkaya, Hande Mefkure ; Hatemi, Ali Ibrahim ; Kadioglu, Pinar</creatorcontrib><description>Purpose
To evaluate the effects of somatostatin analogs and disease activity status on the upper gastrointestinal system in patients with acromegaly.
Methods
One hundred eighty-one patients with acromegaly were retrospectively assessed. The demographic, biochemical, pathologic, and radiologic data of the patients were evaluated. The upper gastrointestinal endoscopies and endoscopic biopsies were investigated. We divided patients into four groups according to the use of somatostatin analogs, and into two groups according to disease activity. We compared the data of patients between groups A, B, C, and D, and controlled/uncontrolled groups separately.
Results
Before and in the peri-endoscopic period, 67 and 27 patients were being treated with octreotide long-acting release (LAR) (group A) and lanreotide autogel (group B), respectively. Twenty-one patients used somatostatin analogs, but they were stopped for various reasons before upper gastrointestinal endoscopy (group C), and 66 patients did not use a somatostatin analog (group D). In the peri-endoscopic period, 103 (60%) patients were responsive to medical and/or surgical treatment and 67 (40%) patients were non-responsive. The rate of gastritis was higher in group A than in groups B and D. The incidence of duodenitis and gastric ulcer was much higher in group D. The rate of gastritis was higher in the controlled group compared to the uncontrolled group.
Conclusion
The study showed that octreotide LAR treatment could be a risk factor in addition to known factors for the development of gastritis in patients with acromegaly.</description><identifier>ISSN: 1386-341X</identifier><identifier>EISSN: 1573-7403</identifier><identifier>DOI: 10.1007/s11102-020-01095-3</identifier><identifier>PMID: 33074400</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Acromegaly ; Duodenitis ; Endocrinology ; Endoscopy ; Gastritis ; Human Physiology ; Medicine ; Medicine & Public Health ; Octreotide ; Patients ; Risk factors ; Somatostatin</subject><ispartof>Pituitary, 2021-04, Vol.24 (2), p.184-191</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020</rights><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-9db5e7a1ad86074b158a1f3de7d00697ffcf89e9d7c00e4768f04551ef818dd03</citedby><cites>FETCH-LOGICAL-c375t-9db5e7a1ad86074b158a1f3de7d00697ffcf89e9d7c00e4768f04551ef818dd03</cites><orcidid>0000-0002-8329-140X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11102-020-01095-3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11102-020-01095-3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33074400$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sahin, Serdar</creatorcontrib><creatorcontrib>Icli, Tevhide Betul</creatorcontrib><creatorcontrib>Durcan, Emre</creatorcontrib><creatorcontrib>Sulu, Cem</creatorcontrib><creatorcontrib>Ozkaya, Hande Mefkure</creatorcontrib><creatorcontrib>Hatemi, Ali Ibrahim</creatorcontrib><creatorcontrib>Kadioglu, Pinar</creatorcontrib><title>The effect of somatostatin analogs and acromegaly on the upper gastrointestinal system</title><title>Pituitary</title><addtitle>Pituitary</addtitle><addtitle>Pituitary</addtitle><description>Purpose
To evaluate the effects of somatostatin analogs and disease activity status on the upper gastrointestinal system in patients with acromegaly.
Methods
One hundred eighty-one patients with acromegaly were retrospectively assessed. The demographic, biochemical, pathologic, and radiologic data of the patients were evaluated. The upper gastrointestinal endoscopies and endoscopic biopsies were investigated. We divided patients into four groups according to the use of somatostatin analogs, and into two groups according to disease activity. We compared the data of patients between groups A, B, C, and D, and controlled/uncontrolled groups separately.
Results
Before and in the peri-endoscopic period, 67 and 27 patients were being treated with octreotide long-acting release (LAR) (group A) and lanreotide autogel (group B), respectively. Twenty-one patients used somatostatin analogs, but they were stopped for various reasons before upper gastrointestinal endoscopy (group C), and 66 patients did not use a somatostatin analog (group D). In the peri-endoscopic period, 103 (60%) patients were responsive to medical and/or surgical treatment and 67 (40%) patients were non-responsive. The rate of gastritis was higher in group A than in groups B and D. The incidence of duodenitis and gastric ulcer was much higher in group D. The rate of gastritis was higher in the controlled group compared to the uncontrolled group.
Conclusion
The study showed that octreotide LAR treatment could be a risk factor in addition to known factors for the development of gastritis in patients with acromegaly.</description><subject>Acromegaly</subject><subject>Duodenitis</subject><subject>Endocrinology</subject><subject>Endoscopy</subject><subject>Gastritis</subject><subject>Human Physiology</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Octreotide</subject><subject>Patients</subject><subject>Risk factors</subject><subject>Somatostatin</subject><issn>1386-341X</issn><issn>1573-7403</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kM1r3DAQxUVoyObrH-ghCHrpxc2MZVnysYQ0KQR6SUJvQmuNtrvY1kaSD_vfR-nmA3roaQTze2-eHmOfEb4hgLpMiAh1BTVUgNDJShywY5RKVKoB8am8hW4r0eDvBTtJaQOFAtEcsYUQoJoG4Jg93v8hTt5Tn3nwPIXR5pCyzeuJ28kOYZXKdNz2MYy0ssOOh4nnIpq3W4p8ZVOOYT1lSkViB552KdN4xg69HRKdv85T9vDj-v7qtrr7dfPz6vtd1Qslc9W5pSRl0TrdlkRLlNqiF46UA2g75X3vdUedUz0ANarVHhopkbxG7RyIU_Z177uN4WkuGcy4Tj0Ng50ozMnUjayhQ93qgn75B92EOZbIhZKAbQt1h4Wq91T5b0qRvNnG9WjjziCYl9bNvnVTWjd_WzeiiC5ereflSO5d8lZzAcQeSGU1rSh-3P6P7TP14Y0Z</recordid><startdate>20210401</startdate><enddate>20210401</enddate><creator>Sahin, Serdar</creator><creator>Icli, Tevhide Betul</creator><creator>Durcan, Emre</creator><creator>Sulu, Cem</creator><creator>Ozkaya, Hande Mefkure</creator><creator>Hatemi, Ali Ibrahim</creator><creator>Kadioglu, Pinar</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8329-140X</orcidid></search><sort><creationdate>20210401</creationdate><title>The effect of somatostatin analogs and acromegaly on the upper gastrointestinal system</title><author>Sahin, Serdar ; Icli, Tevhide Betul ; Durcan, Emre ; Sulu, Cem ; Ozkaya, Hande Mefkure ; Hatemi, Ali Ibrahim ; Kadioglu, Pinar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-9db5e7a1ad86074b158a1f3de7d00697ffcf89e9d7c00e4768f04551ef818dd03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Acromegaly</topic><topic>Duodenitis</topic><topic>Endocrinology</topic><topic>Endoscopy</topic><topic>Gastritis</topic><topic>Human Physiology</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Octreotide</topic><topic>Patients</topic><topic>Risk factors</topic><topic>Somatostatin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sahin, Serdar</creatorcontrib><creatorcontrib>Icli, Tevhide Betul</creatorcontrib><creatorcontrib>Durcan, Emre</creatorcontrib><creatorcontrib>Sulu, Cem</creatorcontrib><creatorcontrib>Ozkaya, Hande Mefkure</creatorcontrib><creatorcontrib>Hatemi, Ali Ibrahim</creatorcontrib><creatorcontrib>Kadioglu, Pinar</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Pituitary</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sahin, Serdar</au><au>Icli, Tevhide Betul</au><au>Durcan, Emre</au><au>Sulu, Cem</au><au>Ozkaya, Hande Mefkure</au><au>Hatemi, Ali Ibrahim</au><au>Kadioglu, Pinar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The effect of somatostatin analogs and acromegaly on the upper gastrointestinal system</atitle><jtitle>Pituitary</jtitle><stitle>Pituitary</stitle><addtitle>Pituitary</addtitle><date>2021-04-01</date><risdate>2021</risdate><volume>24</volume><issue>2</issue><spage>184</spage><epage>191</epage><pages>184-191</pages><issn>1386-341X</issn><eissn>1573-7403</eissn><abstract>Purpose
To evaluate the effects of somatostatin analogs and disease activity status on the upper gastrointestinal system in patients with acromegaly.
Methods
One hundred eighty-one patients with acromegaly were retrospectively assessed. The demographic, biochemical, pathologic, and radiologic data of the patients were evaluated. The upper gastrointestinal endoscopies and endoscopic biopsies were investigated. We divided patients into four groups according to the use of somatostatin analogs, and into two groups according to disease activity. We compared the data of patients between groups A, B, C, and D, and controlled/uncontrolled groups separately.
Results
Before and in the peri-endoscopic period, 67 and 27 patients were being treated with octreotide long-acting release (LAR) (group A) and lanreotide autogel (group B), respectively. Twenty-one patients used somatostatin analogs, but they were stopped for various reasons before upper gastrointestinal endoscopy (group C), and 66 patients did not use a somatostatin analog (group D). In the peri-endoscopic period, 103 (60%) patients were responsive to medical and/or surgical treatment and 67 (40%) patients were non-responsive. The rate of gastritis was higher in group A than in groups B and D. The incidence of duodenitis and gastric ulcer was much higher in group D. The rate of gastritis was higher in the controlled group compared to the uncontrolled group.
Conclusion
The study showed that octreotide LAR treatment could be a risk factor in addition to known factors for the development of gastritis in patients with acromegaly.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>33074400</pmid><doi>10.1007/s11102-020-01095-3</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-8329-140X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1386-341X |
| ispartof | Pituitary, 2021-04, Vol.24 (2), p.184-191 |
| issn | 1386-341X 1573-7403 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2452091868 |
| source | Springer Nature - Complete Springer Journals |
| subjects | Acromegaly Duodenitis Endocrinology Endoscopy Gastritis Human Physiology Medicine Medicine & Public Health Octreotide Patients Risk factors Somatostatin |
| title | The effect of somatostatin analogs and acromegaly on the upper gastrointestinal system |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T06%3A15%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20effect%20of%20somatostatin%20analogs%20and%20acromegaly%20on%20the%20upper%20gastrointestinal%20system&rft.jtitle=Pituitary&rft.au=Sahin,%20Serdar&rft.date=2021-04-01&rft.volume=24&rft.issue=2&rft.spage=184&rft.epage=191&rft.pages=184-191&rft.issn=1386-341X&rft.eissn=1573-7403&rft_id=info:doi/10.1007/s11102-020-01095-3&rft_dat=%3Cproquest_cross%3E2501660291%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2501660291&rft_id=info:pmid/33074400&rfr_iscdi=true |